ArticleNAR cancer2022
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.
Article in NAR cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.Molecular cancer · 2026Review
- Acquired resistance in cancer: towards targeted therapeutic strategies.Nature reviews. Cancer · 2025Review
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- The roles of patient-derived xenograft models and artificial intelligence toward precision medicine.MedComm · 2024Review
- XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.Nature communications · 2024Article
- A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.Cancer research · 2024Article
- Patient-Derived-Xenografts in Mice: A Preclinical Platform for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Nextflow pipeline for Visium and H&E data from patient-derived xenograft samples.Cell reports methods · 2024Article
- NCI Cancer Research Data Commons: Cloud-Based Analytic Resources.Cancer research · 2024Review
- Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Alteration in molecular properties during establishment and passaging of endometrial carcinoma patient-derived xenografts.Scientific reports · 2023Article
- Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials.Tomography (Ann Arbor, Mich.) · 2023Article
- PDCM Finder: an open global research platform for patient-derived cancer models.Nucleic acids research · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
43 authors at 11 institutions in 1 country.
Funding
Abstract
We created the PDX Network (PDXNet) portal (https://portal.pdxnetwork.org/) to centralize access to the National Cancer Institute-funded PDXNet consortium resources, to facilitate collaboration among researchers and to make these data easily available for research. The portal includes sections for resources, analysis results, metrics for PDXNet activities, data processing protocols and training materials for processing PDX data. Currently, the portal contains PDXNet model information and data resources from 334 new models across 33 cancer types. Tissue samples of these models were deposited in the NCI's Patient-Derived Model Repository (PDMR) for public access. These models have 2134 associated sequencing files from 873 samples across 308 patients, which are hosted on the Cancer Genomics Cloud powered by Seven Bridges and the NCI Cancer Data Service for long-term storage and access with dbGaP permissions. The portal includes results from freely available, robust, validated and standardized analysis workflows on PDXNet sequencing files and PDMR data (3857 samples from 629 patients across 85 disease types). The PDXNet portal is continuously updated with new data and is of significant utility to the cancer research community as it provides a centralized location for PDXNet resources, which support multi-agent treatment studies, determination of sensitivity and resistance mechanisms, and preclinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.